MeSH term
Frequency | Condition_Probility | Humans | 47 | 0.0 |
Research Support, Non-U.S. Gov't | 33 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 24 | 0.0 |
Receptor, EphA2 | 9 | 75.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 14 | 0.0 |
Tumor Cells, Cultured | 14 | 0.0 |
Ephrin-A1 | 5 | 71.0 |
Immunohistochemistry | 10 | 0.0 |
Predictive Value of Tests | 2 | 0.0 |
Prognosis | 3 | 0.0 |
Proteins/*metabolism | 2 | 0.0 |
Receptor Protein-Tyrosine Kinases/*metabolism | 3 | 1.0 |
Survival Analysis | 2 | 0.0 |
Base Sequence | 3 | 0.0 |
Ephrin-A2 | 3 | 30.0 |
Glycosylphosphatidylinositols/metabolism | 2 | 3.0 |
Kinetics | 2 | 0.0 |
Molecular Sequence Data | 6 | 0.0 |
Phosphorylation | 11 | 0.0 |
Phosphotyrosine/metabolism | 2 | 0.0 |
Time Factors | 4 | 0.0 |
RNA, Neoplasm/biosynthesis | 2 | 1.0 |
Up-Regulation | 5 | 0.0 |
Neoplasm Staging | 4 | 0.0 |
Blotting, Northern | 2 | 0.0 |
Blotting, Western | 6 | 0.0 |
Cell Line, Tumor | 5 | 0.0 |
Female | 16 | 0.0 |
Male | 9 | 0.0 |
Receptor, EphA2/*biosynthesis | 3 | 100.0 |
Reverse Transcriptase Polymerase Chain Reaction | 5 | 0.0 |
Oligonucleotides, Antisense/pharmacology | 2 | 0.0 |
Tyrosine/metabolism | 3 | 0.0 |
Animals | 16 | 0.0 |
Breast Neoplasms/*enzymology/pathology | 2 | 6.0 |
Cell Adhesion/physiology | 3 | 1.0 |
Ligands | 7 | 0.0 |
Mice | 13 | 0.0 |
Mice, Nude | 6 | 0.0 |
Adult | 5 | 0.0 |
Aged | 5 | 0.0 |
Aged, 80 and over | 4 | 0.0 |
Middle Aged | 6 | 0.0 |
Neoplasm Invasiveness | 4 | 0.0 |
*Adaptor Proteins, Signal Transducing | 2 | 0.0 |
Cells, Cultured | 6 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
Jurkat Cells | 2 | 0.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Neoplasm Transplantation | 2 | 0.0 |
Signal Transduction | 3 | 0.0 |
Cell Division/drug effects | 2 | 0.0 |
Cell Movement/drug effects | 2 | 0.0 |
Gelatinase A/*metabolism | 2 | 6.0 |
Protein-Tyrosine Kinase/*metabolism | 2 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
COS Cells | 2 | 0.0 |
Cell Adhesion | 2 | 0.0 |
Cell Movement | 3 | 0.0 |
Protein Binding | 3 | 0.0 |
Amino Acid Sequence | 4 | 0.0 |
Cell Line | 3 | 0.0 |
In Situ Hybridization | 2 | 0.0 |
Sequence Homology, Amino Acid | 3 | 0.0 |
Gene Expression Profiling | 3 | 0.0 |
Gene Expression | 2 | 0.0 |
Receptor, EphA2/*metabolism | 3 | 100.0 |
Neoplasm Metastasis | 3 | 0.0 |
Epitope Mapping | 2 | 0.0 |
Epitopes, T-Lymphocyte/immunology | 2 | 2.0 |
Lymphocyte Activation/immunology | 2 | 0.0 |
Xenograft Model Antitumor Assays | 2 | 0.0 |
Protein p53/metabolism | 2 | 0.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Mitogen-Activated Protein Kinases/drug effects/*metabolism | 2 | 14.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Laminin/metabolism | 2 | 1.0 |
Neovascularization, Pathologic | 3 | 0.0 |
